- Home
- INAB vs TLPH Comparison
INAB vs TLPH Comparison
Compare INAB & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- TLPH
- Stock Information
- Founded
- INAB 2016
- TLPH 2005
- Country
- INAB United States
- TLPH United States
- Employees
- INAB N/A
- TLPH N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- TLPH Health Care
- Exchange
- INAB Nasdaq
- TLPH Nasdaq
- Market Cap
- INAB 10.6M
- TLPH 11.1M
- IPO Year
- INAB 2021
- TLPH 2011
- Fundamental
- Price
- INAB $2.08
- TLPH $1.17
- Analyst Decision
- INAB Strong Buy
- TLPH Strong Buy
- Analyst Count
- INAB 2
- TLPH 1
- Target Price
- INAB $108.00
- TLPH $6.00
- AVG Volume (30 Days)
- INAB 67.4K
- TLPH 463.2K
- Earning Date
- INAB 11-11-2025
- TLPH 11-12-2025
- Dividend Yield
- INAB N/A
- TLPH N/A
- EPS Growth
- INAB N/A
- TLPH N/A
- EPS
- INAB N/A
- TLPH N/A
- Revenue
- INAB N/A
- TLPH $27,000.00
- Revenue This Year
- INAB N/A
- TLPH N/A
- Revenue Next Year
- INAB N/A
- TLPH $14,533.26
- P/E Ratio
- INAB N/A
- TLPH N/A
- Revenue Growth
- INAB N/A
- TLPH N/A
- 52 Week Low
- INAB $1.91
- TLPH $0.38
- 52 Week High
- INAB $12.53
- TLPH $1.45
- Technical
- Relative Strength Index (RSI)
- INAB 46.89
- TLPH 60.93
- Support Level
- INAB $2.09
- TLPH $1.12
- Resistance Level
- INAB $2.16
- TLPH $1.19
- Average True Range (ATR)
- INAB 0.13
- TLPH 0.12
- MACD
- INAB -0.01
- TLPH -0.02
- Stochastic Oscillator
- INAB 13.11
- TLPH 31.45
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.